Sutrimet

Therapeutic indications:

The drug is used for therapeutic purposes in calves for colisepticemia, salmonellosis, pasteurellosis, bronchopneumonia, abscesses caused by staphylococci, and polyarthritis caused by streptococci; in pigs for escherichiosis (colibacillosis), infectious atrophic rhinitis, salmonellosis, pasteurellosis, toxoplasmosis, and actinobacillary pleuropneumonia; in poultry (broiler chickens and replacement pullets) for colisepticemia, pasteurellosis, escherichiosis (colibacillosis), salmonellosis, staphylococcosis, and eimeriosis.

Pharmacotherapeutic group:

Sulfonamides in combinations. 

Dosage form description

Suspension for oral administration. In appearance, the drug is a white to light yellow suspension.

1-liter polymer bottles and 5-liter canisters. 

Composition of the veterinary drug:

1 ml of the drug contains 400 mg of sulfamonomethoxine sodium and 80 mg of trimethoprim as active ingredients. 

Pharmacological activity:

Sulfamonomethoxine and trimethoprim possess a broad spectrum of activity against gram-negative and gram-positive microorganisms, including the majority of Streptococcus spp., Staphylococcus spp., Escherichia coli, Shigella spp., and others, as well as certain protozoa such as Eimeria spp. and Toxoplasma gondii.

Sulfamonomethoxine is structurally similar to para-aminobenzoic acid, disrupts the synthesis of dihydrofolic acid in bacterial cells by preventing the incorporation of para-aminobenzoic acid into its molecule. Trimethoprim inhibits the reduction of dihydrofolic acid into tetrahydrofolic acid, which is the active form of folic acid responsible for protein metabolism and microbial cell division. Their combined action disrupts folic acid synthesis at two consecutive stages, leading to a disruption in nucleotide synthesis and resulting in a synergistic bactericidal effect of the combination of sulfamonomethoxine and trimethoprim. The active ingredients of the drug are rapidly absorbed from the gastrointestinal tract and penetrate into all organs and tissues of the body, where they remain at therapeutic concentrations for 24 hours. They are excreted from the body primarily via urine, and to a lesser extent via bile. 

Dosage:

The drug is administered orally individually or in group methods via drinking water in the following doses:

• for calves and pigs: 1–2 ml of the drug per 32 kg of animal body weight for 5 days
• for poultry: for eimeriosis, 0.2–0.3 ml of the drug per 1 kg of bird body weight (corresponding to 100 ml of the drug per 100 l of drinking water) for 3–5 days; for bacterial diseases, 1 ml of the drug per 32 kg of bird body weight for 5 days.

During group administration, animals and poultry must receive only drinking water containing the drug. During individual administration, the daily dose of the drug should be divided into two equal parts and given to animals in two intakes, with an interval of 12 hours. The solution with the drug is prepared fresh daily during the treatment period. Before use, the bottle/canister containing the drug must be shaken. 

Contraindications:

Contraindicated for use in animals and poultry with increased individual sensitivity to the components of the drug, in laying hens, as well as in animals and poultry with impaired renal and hepatic function. 

Overdose:

Symptoms of overdose during the use of the drug in animals and poultry have not been identified. 

Pregnancy and lactation:

The drug can be used in pregnant and lactating sows and in poultry intended for breeding. 

Special indications:

No specific features of action upon the first use of the drug or upon its withdrawal have been identified. Skipping regular administration of the drug to animals and poultry should be avoided, as this may lead to a decrease in therapeutic efficacy. If a dose is missed, the course of administration must be resumed in accordance with the prescribed dose and treatment regimen. Do not compensate for a missed application of the drug by increasing the dose. 

Side effects and individual intolerance:

Adverse events and complications are generally not observed when using the drug in accordance with this instruction. In animals with increased individual sensitivity to the components of the drug, allergic reactions may occur. In this case, use of the drug is discontinued and antihistamines are prescribed. 

Interaction with other veterinary medicinal drugs:

Contraindicated for simultaneous use with para-aminobenzoic acid derivatives, such as local anesthetics: procaine, tetracaine, procainamide, etc. The drug should not be used with B-group vitamins (nicotinamide, folic acid, choline) due to their antagonistic action on sulfonamides. 

Withdrawal period:

Slaughter of animals for meat is permitted no earlier than 10 days, poultry for eimeriosis no earlier than 10 days, and for bacterial diseases no earlier than 4 days after the last use of the drug. In the case of forced slaughter of animals and poultry before the specified period, the meat may be used as feed for carnivorous animals. The use of the drug is prohibited in poultry (during the egg-laying period) whose eggs are intended for human consumption. 

Shelf-life:

3 years from the date of manufacture. Use of the drug after the expiration date is prohibited. 

Storage conditions:

Store in a dry place protected from light at temperatures from 2 °C to 25 °C. The drug should be stored in a place out of reach of children. After the first opening of the bottle/canister, use within 2 months under compliance with storage conditions. The prepared solution is valid for 24 hours.